{"id":627412,"date":"2024-03-13T11:22:34","date_gmt":"2024-03-13T15:22:34","guid":{"rendered":"https:\/\/www.singlecare.com\/blog\/?p=627412"},"modified":"2024-10-25T10:03:35","modified_gmt":"2024-10-25T14:03:35","slug":"jubbonti-wyost-fda-approval","status":"publish","type":"post","link":"https:\/\/www.singlecare.com\/blog\/news\/jubbonti-wyost-fda-approval\/","title":{"rendered":"FDA approves first biosimilars to Prolia and Xgeva"},"content":{"rendered":"

On Mar. 5, 2024, the <\/span>U.S. Food & Drug Administration (FDA) approved<\/span><\/a> Jubbonti and Wyost, the first interchangeable <\/span>biosimilars<\/span><\/a> to the injectable medications <\/span>Prolia<\/span><\/a> and <\/span>Xgeva<\/span><\/a>, respectively. <\/span><\/p>\n

As RANKL inhibitors, these drugs help target and bind to a protein in a way that prevents bone cells called osteoclasts from breaking down bone in the body. <\/span>Osteoporosis<\/span><\/a> and <\/span>bone density<\/span><\/a> conditions are common in the U.S.—the <\/span>Centers for Disease Control and Prevention (CDC) estimates<\/span><\/a> 1 in 5 women ages 50 and older have it—and these medications are crucial for treatment. <\/span><\/p>\n

With the approval of Jubbonti (denosumab-bbdz) and Wyost (denosumab-bbdz), patients on Prolia or Xgeva may have a less expensive and more accessible treatment option as biosimilar and interchangeable biosimilar products may cost less than their brand-name counterparts. <\/span><\/p>\n

What is Prolia?<\/span><\/h2>\n

Prolia<\/span><\/a> (denosumab) is a subcutaneous injection that is administered by a healthcare professional every six months. According to a <\/span>10-year review of clinical studies<\/span><\/a>, it is a highly effective anti-osteoporosis therapy for patients at high risk of fracture. <\/span><\/p>\n

Prolia is approved by the FDA to:<\/span><\/p>\n